Trial Profile
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Technetium tc 99m trofolastat (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use; Registrational
- Acronyms proSPECT-AS
- Sponsors Molecular Insight Pharmaceuticals
- 18 May 2020 Results (n=87) of a secondary analysis presented at the 115th Annual Meeting of the American Urological Association
- 24 Jun 2019 Results of retrospective analysis, presented in a Progenics Pharmaceuticals media release.
- 24 Jun 2019 According to a Progenics Pharmaceuticals media release, results of retrospective analysis from the study were presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2019 Annual Meeting.